December 4, 2025

Neurizon completes GMP batches of NUZ-001, enabling FDA Rolling Review and supplying the drug’s entry into the HEALEY ALS Platform Trial in 2026. The program advances regulatory readiness for a major ALS therapy candidate. ASX NUZ

Neurizon Pushes NUZ-001 Toward FDA Submission After Completing Tablet Batches

December 4, 2025

Neurizon Therapeutics (ASX: NUZ & OTCQB: NUZTF) has completed manufacturing three Good Manufacturing Practice (GMP) registration batches of its NUZ-001 […]

Larvotto installs ECORE technology at Hillgrove, delivering real-time mineral analysis to accelerate exploration, metallurgical design and antimony-gold development. LRV ASX

Resources

Larvotto Deploys ECORE Technology to Hasten Hillgrove Development

December 4, 2025

Larvotto Resources (ASX: LRV) has installed the ECORE core scanning system at its Hillgrove Antimony & Gold Project in New